Skip to main content
eScholarship
Open Access Publications from the University of California

The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations

  • Author(s): Amendola, LM
  • Berg, JS
  • Horowitz, CR
  • Angelo, F
  • Bensen, JT
  • Biesecker, BB
  • Biesecker, LG
  • Cooper, GM
  • East, K
  • Filipski, K
  • Fullerton, SM
  • Gelb, BD
  • Goddard, KAB
  • Hailu, B
  • Hart, R
  • Hassmiller-Lich, K
  • Joseph, G
  • Kenny, EE
  • Koenig, BA
  • Knight, S
  • Kwok, PY
  • Lewis, KL
  • McGuire, AL
  • Norton, ME
  • Ou, J
  • Parsons, DW
  • Powell, BC
  • Risch, N
  • Robinson, M
  • Rini, C
  • Scollon, S
  • Slavotinek, AM
  • Veenstra, DL
  • Wasserstein, MP
  • Wilfond, BS
  • Hindorff, LA
  • Plon, SE
  • Jarvik, GP
  • et al.
Abstract

© 2018 American Society of Human Genetics The Clinical Sequencing Evidence-Generating Research (CSER) consortium, now in its second funding cycle, is investigating the effectiveness of integrating genomic (exome or genome) sequencing into the clinical care of diverse and medically underserved individuals in a variety of healthcare settings and disease states. The consortium comprises a coordinating center, six funded extramural clinical projects, and an ongoing National Human Genome Research Institute (NHGRI) intramural project. Collectively, these projects aim to enroll and sequence over 6,100 participants in four years. At least 60% of participants will be of non-European ancestry or from underserved settings, with the goal of diversifying the populations that are providing an evidence base for genomic medicine. Five of the six clinical projects are enrolling pediatric patients with various phenotypes. One of these five projects is also enrolling couples whose fetus has a structural anomaly, and the sixth project is enrolling adults at risk for hereditary cancer. The ongoing NHGRI intramural project has enrolled primarily healthy adults. Goals of the consortium include assessing the clinical utility of genomic sequencing, exploring medical follow up and cascade testing of relatives, and evaluating patient-provider-laboratory level interactions that influence the use of this technology. The findings from the CSER consortium will offer patients, healthcare systems, and policymakers a clearer understanding of the opportunities and challenges of providing genomic medicine in diverse populations and settings, and contribute evidence toward developing best practices for the delivery of clinically useful and cost-effective genomic sequencing in diverse healthcare settings.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View